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Background: Treatment failure is a critical issue in breast cancer and identifying useful interventions that optimize
current cancer therapies remains a critical unmet need. Expression and functional studies have identified connexins
(Cxs), a family of gap junction proteins, as potential tumor suppressors. Studies suggest that Cx43 has a role in
breast cancer cell proliferation, differentiation, and migration. Although pan-gap junction drugs are available, the
lack of specificity of these agents increases the opportunity for off target effects. Consequently, a therapeutic agent
that specifically modulates Cx43 would be beneficial and has not been tested in breast cancer. In this study, we
now test an agent that specifically targets Cx43, called ACT1, in breast cancer.
Methods: We evaluated whether direct modulation of Cx43 using a Cx43-directed therapeutic peptide, called
ACT1, enhances Cx43 gap junctional activity in breast cancer cells, impairs breast cancer cell proliferation or survival,
and enhances the activity of the targeted inhibitors tamoxifen and lapatinib.
Results: Our results show that therapeutic modulation of Cx43 by ACT1 maintains Cx43 at gap junction sites
between cell-cell membrane borders of breast cancer cells and augments gap junction activity in functional assays.
The increase in Cx43 gap junctional activity achieved by ACT1 treatment impairs proliferation or survival of breast
cancer cells but ACT1 has no effect on non-transformed MCF10A cells. Furthermore, treating ER+ breast cancer cells
with a combination of ACT1 and tamoxifen or HER2+ breast cancer cells with ACT1 and lapatinib augments the
activity of these targeted inhibitors.
Conclusions: Based on our findings, we conclude that modulation of Cx43 activity in breast cancer can be
effectively achieved with the agent ACT1 to sustain Cx43-mediated gap junctional activity resulting in impaired
malignant progression and enhanced activity of lapatinib and tamoxifen, implicating ACT1 as part of a combination
regimen in breast cancer.
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Gap junctions are specialized membrane channels that
facilitate intercellular communication through the
exchange of ions, second messengers, and small metabo-
lites (generally < 1 kDa in size) between neighboring cells
and enable electrical propagation in excitable tissues [1].
The core protein components of gap junction channels
are connexins (Cxs), tetraspan transmembrane proteins
containing two extracellular loops, a cytoplasmic loop,
and cytoplasmic N-terminal and C-terminal domains.
Six connexins oligomerize to form cored transmembrane
hemichannels that couple with hemichannels on neigh-
boring cells to form intercellular channels. In turn, these
intercellular channels aggregate to form gap junctions
[2,3]. The human genome encodes for 21 connexin genes,
each with a tissue and cell-type specific expression pattern.
Gap junctions have a widely recognized role in tumori-
genesis and the progression of metastatic disease where
research has highlighted individual connexin proteins as
potential tumor suppressors that regulate tumor cell
proliferation and tumor growth in vivo [4]. Several stud-
ies have implicated Cx43 in mammary gland develop-
ment [5-10] and investigated Cx43 expression in breast
cancer cells or human breast cancer tissues [5,11-18].
These studies propose that Cx43 has a role in breast
cancer cell proliferation, differentiation, and migration.
Additionally, studies that examine human breast cancer
tissue indicate that Cx43 expression patterns fluctuate
with cancer stage [14-16,19]. These studies also suggest
that decreased Cx43 localization to gap junctions can
mediate disease severity independently of Cx43 expres-
sion levels and thus loss of Cx43 at gap junctions could
act as a biomarker of malignancy [14-17,19]. Conse-
quently, maintaining Cx43 function at gap junctions,
thereby preserving gap junction intercellular communi-
cation, has the potential to attenuate malignant trans-
formation and metastatic progression [14,16,17].
Unfortunately, the development and evaluation of thera-
peutic interventions aimed at targeting Cx43 in breast
cancers is complicated due to evidence that connexins may
have differential and dynamic roles during tumor cell dis-
semination. The loss of gap junction intercellular commu-
nication corresponds with the initial stages of malignant
phenotype progression in neoplastic mammary tissue and
may be related to changes in cell-cell adhesion. Consistent
with this concept, it has been reported that the loss of gap
junctions contributes toward allowing cells to physically
detach leading to invasion and metastatic disease progres-
sion [4,20-22]. Conversely, reports indicate that Cx43 is up-
regulated in established breast cancer metastatic lesions,
suggesting that connexins may play roles in late metastatic
steps involving extravasation and tissue colonization
[11,15,23,24]. Additionally, Cx43 expression has been
shown to shift to stromal compartments during cancerprogression, suggesting that Cx43 may be regulating
invasion and metastasis through interactions between
epithelial tumor cells and the stroma [25]. It is import-
ant to acknowledge that conflicting data likely repre-
sent differences in experimental approaches, the
cellular heterogeneity of tumors, the overlapping roles
of other connexin family members, and the complexity
of the metastatic process.
It is likely that channel-independent functions also
contribute to Cx43’s role in breast cancer. Because it is
possible that differential activities for Cx43 are rele-
vant in breast cancer, a method for examining en-
dogenous Cx43 activity at gap junctions would be
instrumental in clarifying the role of Cx43 in breast
cancer and the therapeutic potential of targeting this
molecule. However, studies examining the role of Cx43
in mammary/breast cells have used either drugs aimed
at the global inhibition of gap junction activity that are
not specific for Cx43, or overexpression constructs,
which alter Cx43 mRNA and protein expression levels
therefore adding an additional variable to experimental
interpretation [6,26-32].
In order to specifically examine endogenous Cx43 ac-
tivity at gap junctions without altering expression levels,
we have employed a unique 25-amino acid length pep-
tide drug (ACT1) that mimics a cytoplasmic regulatory
domain of Cx43. ACT1 redirects uncoupled Cx43 hemi-
channels into gap junctions, thereby reducing gap junc-
tion turnover and enhancing gap junction aggregation,
without effecting Cx43 protein levels [33,34]. Conse-
quently, ACT1 provides the desired characteristics of
separating Cx43 expression levels from Cx43 function,
in order to study the gap-junctional activity of Cx43 in
breast cancer. Here, we present evidence demonstrating
that ACT1-mediated augmentation of Cx43-composed
gap junctions impairs proliferation or induces apoptosis
in breast cancer cells but not in non-transformed mam-
mary epithelial cells, confirming a tumor suppressive
function for Cx43.
Furthermore, stabilizing junctional Cx43 and modulating
gap junctional intercellular communication in cancer cells
has been suggested to elicit a “bystander” effect, where
increases in the number or size of gap junctions and
enhanced gap junctional intercellular communication result
in increased diffusion of cytotoxic agents, sensitization to
chemotherapeutics, and an amplification of therapeutic
response [4,35]. Supporting this assertion, re-expression of
Cx43 in human cancer cells has been shown to increase
cancer cell sensitivity to common chemotherapeutic agents
[36,37]. Conversely, a recent study by Munoz et al. showed
that Cx43 levels were increased in temozolomide-resistant
Glioblastoma Multiforme cells implying that gap junc-
tion intercellular communication between the resistant
cells due to the increase in Cx43 might contribute to
Grek et al. BMC Cancer  (2015) 15:296 Page 3 of 13the development of temozolomide resistance [38]. These
conflicting results could be due to differences in experi-
mental system (i.e. breast versus brain) or highlight non-
junctional activities of Cx43 in Glioblastoma Multiforme, as
we now provide evidence to show that modulation of Cx43
signaling with ACT1 effectively increases gap junctional
intercellular communication in breast cancer cells, and en-
hances drug-induced cytotoxicity of the targeted therapies
tamoxifen in the ER+ MCF7 breast cancer cell line and
lapatinib in the HER2+ BT474 breast cancer cell line. Our
results demonstrate that modulation of Cx43-based gap
junctional activity and distribution by ACT1 impairs breast
cancer cell proliferation or survival and highlights




MCF10A cells were maintained in DMEM (Hyclone)
supplemented with FBS (Gibco), 10 ng/ml EGF, 5 μg/ml
insulin, and 1 μg/ml hydrocortisone. MCF7 cells were
maintained in DMEM (Hyclone) supplemented with FBS
(Gibco). MDA MB 231 cells were maintained in Leibovitz
supplemented with FBS (Gibco). BT474 cells were main-
tained in RPMI-1640 supplemented with FBS (Gibco). All
media contained 2 mM glutamine (Thermo Scientific) and
Penicillin/Streptomycin (Pen/Strep, Thermo Scientific) un-
less otherwise specified.
Therapeutic peptides
α–connexin carboxyl-terminal (ACT1) peptide and its
reverse sequence peptide (R-pep) were synthesized by
the American Peptide Company (Sunnyvale, CA). The
ACT1 peptide corresponds to a short sequence at the
Cx43 C-terminus linked to an antennapedia internalization
sequence (RQPKIWFPNRRKPWKKRPRPDDLEI). Anten-
napedia internalization peptide sequence is RQPKIWFPN
RRKPWKK. R-pep sequence consists of the reverse se-
quence of ACT1 attached to an anntennapedia internaliza-
tion sequence.
Gap-FRAP
Cells were treated with either ACT-1 (200 μM), reverse
peptide (R-pep; 200 μM), or Vehicle (Veh; H2O) for
6 hr. One-half-hour prior to the end of the two hour in-
cubation cells were loaded with calcein-AM. At the end
of the incubation period, cells were washed and imaging
medium (phenol-free Optimem) containing 100 μM of
respective treatments was added to the culture. Cells
were imaged on a Leica SP5 Laser Scanning Confocal
Microscope using the FRAP wizard. Briefly, the cyto-
plasm of a single cell in the imaging field was bleached
with 10 frames of high intensity laser light using all laser
lines. Fluorescence recovery was monitored with 488 nmexcitation every 10 sec over one minute. For BT474 and
MCF7, N = 3 per treatment. For MCF10A, N = 2 per
treatment. 3 replicates per sample per treatment.
Crystal violet stain analysis
Equal numbers of cells were plated and treated the follow-
ing day with ACT1, reverse peptide (R-pep), or Vehicle
(Veh; H2O) for 48 hr. When indicated, cells were also
treated with DMSO (vehicle), tamoxifen (Sigma), or lapa-
tinib (Santa Cruz) prior to analysis. Following drug treat-
ments, cells were fixed in 4% paraformaldehyde and
stained with crystal violet. Cells were subsequently washed
in deionized H2O and crystal violet was extracted with
methanol. A540 was read using Benchmark Plus plate
reader (Biorad).
Cell counting analysis
Equal numbers of cells were plated and treated the follow-
ing day with ACT1, reverse peptide (R-pep), or Vehicle
(Veh; H2O) for 48 hr. When indicated, cells were also
treated with DMSO (vehicle) or tamoxifen citrate (Sigma)
prior to analysis by trypan blue exclusion and cell count-
ing, which was performed using a hemocytometer or the
Cellometer Mini cell counter (Nexcelom).
Mammosphere assay
Mammosphere assay was performed as previously reported
[39]. Briefly, 500 BT474 cells per well were plated into low
adhesion 96 well plates (BrandTech Scientific Inc.). After
3 days in culture, peptides and targeted inhibitors were
added to wells. On day 7 of the experiment, mammosphere
structures were quantitated. Mammosphere forming effi-
ciency was calculated using the formula: (number of mam-
mospheres per well/number of cells seeded per well) × 100,
as previously described [39].
Immunoblotting
Cells were lysed directly into SDS Sample Buffer containing
β-mercaptoethanol. Primary antibodies used for western
blotting are: anti-Cx43 (Sigma, C-terminal directed anti-
body), anti-LC3B (Cell Signaling), anti-pAKT (Santa Cruz),
anti-pERK1/2 (Santa Cruz), anti-cleaved-PARP (Cell
Signaling), anti-ZO1 (cell signaling), anti-Cx26 (Santa
Cruz), anti-Cx46 (Santa Cruz), anti-cleaved-Caspase-3
(Cell Signaling), and anti-β-tubulin (Santa Cruz). Pro-
tein expression levels were evaluated using the Odyssey
imaging system (LICOR).
Statistical analysis
For the gap-FRAP data an ANOVA was performed com-
paring the values at each time point and a Bonferroni post-
hoc analysis was used to determine significance for the
MCF-7 data. In the case of the BT474s a Dunnett’s Mul-
tiple Comparison Test was used. For all other analyses,
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Error of the Mean. For all experiments, N = number of
plates or wells. For some experiments, such as gap-FRAP
analysis, multiple replicates (3 per N) were analyzed within
each plate.
Ethics statement
No human subjects, data, or materials were used in this
study.
Results
ACT1 stabilizes gap junction intercellular communication
in breast cancer cells
Previously it was shown in non-breast cancer cell types
that the therapeutic peptide mimetic ACT1, which tar-
gets Cx43 protein interaction and/or signaling, is able to
increase gap junction hemichannel recruitment and size,
thereby stabilizing gap junction intercellular communi-
cation without altering Cx43 levels [33,34]. To extend
these observations and investigate the role of Cx43 gap
junctions in breast cancer cells, we treated MCF7 cells
with vehicle (water), a non-functional reverse peptide
control (R-pep), or ACT1 and monitored for gap junc-
tional activity using a Fluorescence Recovery After
Photobleaching (FRAP)-based gap junction activity assay
(gap-FRAP). Gap-FRAP measures the diffusion of a gap
junction-permeable fluorescent dye (calcein-AM) allow-
ing for quantitative measurement of gap junctional activ-
ity, since the rate of dye diffusion (i.e. recovery) is
directly proportional to the amount of gap junctions that
are coupled and active. We found that treatment of
MCF7 cells with ACT1 increased dye diffusion mea-
sured by gap-FRAP more robustly than either vehicle or
R-pep (Figure 1A), demonstrating that ACT1 is able toFigure 1 Connexin 43 activity and expression after ACT1 treatment in
ACT1 (200 μM) and assessed for (A) gap-FRAP. ANOVA with Bonferroni pos
0.05 vs Vehicle, τ = p < 0.05 vs R-Pep; ± SEM; n = 3 (B) Immunofluoresence
or ACT1. Wheat germ agglutinin (WGA) in red was used to stain cell membpositively impact gap junction activity in MCF7 cells. These
results were confirmed by immunofluorescence (IF) stain-
ing for Cx43 in R-pep and ACT1 treated MCF7 cells which
showed increased localization of Cx43 protein at the mem-
brane border between neighboring cells in ACT1 treated
cell populations (Figure 1B). Also consistent with previous
findings, we examined total Cx43 protein by immunoblot-
ting extracts from MCF7 cells treated with water, R-pep,
and ACT1 and saw no appreciable difference in overall
Cx43 expression levels (Additional file 1: Figure S1).
It was previously shown that Cx43 inhibits autophagy
and that this function of Cx43 is likely gap junction in-
dependent [36,40]. Therefore, we evaluated whether
ACT1 treatment affects autophagy by examining LC3B
processing in MCF7 cells after ACT1 treatment. We found
no changes in LC3B modification between ACT1 treated
cells and R-pep or water treated cells even in the presence
of the autophagy inhibitor chloroquine (Additional file 1:
Figure S2A). Additional studies indicate that AKT and
MAPK, via ERK1/2, regulate Cx43 and its gap junction ac-
tivity [41-43]. Consequently, we looked at AKT and ERK1/
2 activity by monitoring phosphorylation of these mole-
cules and found that ACT1 treatment did not alter AKT
or ERK1/2 phosphorylation status (Additional file 1:
Figure S2B). Taken together, our results demonstrate that
ACT1 modulates the gap junctional activity of Cx43 by
stabilizing endogenous Cx43 at membrane borders be-
tween cells.
Targeting connexin 43 with ACT1 reduces proliferation of
breast cancer cells
Previous studies have shown that overexpression of
Cx43 decreases proliferation of breast cancer cells and
this observation was attributed to increased localizationMCF7 cells. MCF7 cells were treated with vehicle, R-pep (200 μM), or
t-hoc analyses were used to determine statistical significance * = p <
staining and imaging of Cx43 (green) in MCF7 cells treated with R-pep
ranes.
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vations and that Cx43 has been described as a tumor
suppressor protein in breast cancer [44], we evaluated
the effect of modulating Cx43 with ACT1 on breast can-
cer cell proliferation. MCF7 cells were treated with water
in equal volume or increasing concentrations (50, 100,
and 200 μM) of R-pep or ACT1 for 48 hr and evaluated
for total cell number after treatment. To first demon-
strate that the control R-pep did not have an appreciable
effect on proliferation, we compared vehicle (water)
treated cells and R-pep treated cells at the highest dose
of peptide (200 μM). We found no difference in cell
number after 48 hr of treatment with either of the con-
trol agents (Figure 2A). We next compared total cell
number after treatment between R-pep and ACT1
treated MCF7 cells, and found that cell number was de-
creased in ACT1 (50, 100, and 200 μM) treated MCF7
cells compared to R-pep control at the same dosages
(Figure 2B).
As the aforementioned study also evaluated MDA
MB 231 cells in the context of Cx43 overexpression
[31], we additionally looked at this cell type by theFigure 2 Reduced proliferation of MCF7 and MDA MB 231 cells treate
(200 μM) for 48 hours and assessed for total cell number. (B) MCF7 cells
and total cell number were compared at each drug concentration. (C) M
48 hours and assessed for total cell number. (D) MDA MB 231 cells were treate
number were compared at each drug concentration. Student’s T-test analysis wsame analysis for proliferation. Similar to our findings
in MCF7 cells, we found no effect of vehicle or R-pep
on MDA MB 231 proliferation (Figure 2C) but saw a
decrease in proliferation due to ACT1 (50, 100, and
200uM) treatment (Figure 2D). Taken together, these
findings demonstrate that modulation of Cx43 using
ACT1 impairs breast cancer cell proliferation.Modulation of connexin 43 activity with ACT1 does not
alter proliferation of non-transformed MCF10A mammary
epithelial cells
We next tested whether ACT1 treatment altered the
proliferation of non-cancerous mammary epithelial
cells. Therefore, we the evaluated proliferation of non-
transformed MCF10A mammary epithelial cells treated
with vehicle, R-pep, or ACT1. Equal numbers of cells
were plated and treated with vehicle or 200 μM of R-
pep or ACT1 for 48 hr. First, we evaluated cells by
crystal violet (CV) staining, which revealed that an
equivalent density of cells was present in each well,d with ACT1. (A) MCF7 cells were treated with vehicle or R-pep
were treated for 48 hours with 50, 100, or 200 μM of R-pep or ACT1
DA MB 231 cells were treated with vehicle or R-pep (200 μM) for
d for 48 hours with 50, 100, or 200 μM of R-pep or ACT1 and total cell
as used to determine statistical significance. *p < 0.01; ± SEM; n = 8.
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tated the amount of CV stain in each well as a surro-
gate for total cell number and confirmed that there
was no difference in the percent of total CV stain in
each treatment group (Figure 3B). We additionally
directly quantitated total cell number after perform-
ing the three treatments. Consistent with our obser-
vations in Figure 3A and B, no difference was
observed in the total cell number between treatment
groups (Figure 3C).
To further investigate why the non-transformed
MCF10A cells behave differently compared to MCF7
and MDA MB 231 breast cancer cells in response to
ACT1 treatment, we evaluated Cx43 intracellular distri-
bution by IF and gap junction activity by gap-FRAP in
MCF10A cells after R-pep and ACT1 treatment. We ob-
served very sparse Cx43 staining in MCF10A cells that
was primarily localized to the cytoplasm, rather than at
membrane borders in both R-pep and ACT1 treated
cells (Additional file 1: Figure S3A). We additionally ob-
served little to no gap-FRAP activity in the MCF10A
cells in two independent experiments, suggesting that
these cells are gap junction deficient (Additional file 1:
Figure S3B), which confirmed our observations by IF
and also suggests that Cx43 could have differential func-
tion in non-transformed MCF10A cells. Together, these
findings show that modulating Cx43 in non-cancerous
MCF10A mammary epithelial cells does not alter prolif-
eration, suggesting that ACT1-mediated modulation of
gap junction activity toward reducing proliferation could
be specific to breast cancer cells.Figure 3 ACT1 does not alter proliferation of non-transformed MCF10
R-pep (200 μM), or ACT1 (200 μM) and assessed for (A) crystal violet stainin
by cell counting. ± SEM; n = 6.ACT1 augments tamoxifen treatment of ER+ breast
cancer cells
In addition to being able to inhibit breast cancer cell
proliferation on its own, as a gap junction stabilizer
ACT1 has the added capacity to enhance intercellular
coupling in a manner that promotes exchange of sig-
nals between cells, including cytotoxic signals that are
initiated by cancer drug treatments [35]. This so-called
“bystander” effect could be an added benefit of utiliz-
ing ACT1 for breast cancer treatment. To test this
concept, we assessed dual treatment of MCF7 cells,
which are estrogen receptor positive (ER+), with ACT1
and the ER antagonist tamoxifen. MCF7 cells were
plated in equal number and subsequently treated with
water, (100 μM) R-pep, or (100 μM) ACT1. Each indi-
vidual group of treated cells (i.e. water, R-pep, or
ACT1) was additionally treated with either a vehicle
(DMSO) or 10 μM tamoxifen citrate. After 48 hr of dual
treatment, cells were stained with CV and amount of CV
incorporated into the cells was quantitated by OD540.
Similar to our findings in Figure 2A and B, R-pep by itself
had no effect on MCF7 cell quantity whereas ACT1 alone
reduced the amount of MCF7 cells present (Figure 4A).
When we evaluated vehicle, R-pep, or ACT1 cells that had
also been treated with tamoxifen, we found that tamoxifen
had a greater effect on reducing cell quantity in the ACT1
treatment group (Figure 4A), suggesting that ACT1 aug-
ments the activity of tamoxifen. We corroborated our
results by performing additional experiments that evaluated
total cell number, rather than using CV stain as a surrogate.
Here, cells were treated with R-pep and ACT1 as indicatedA mammary epithelial cells. MCF10A cells were treated with vehicle,
g density and (B) quantitated by OD540. (C) Cells were also assessed
Figure 4 ACT1 cooperates with tamoxifen to promote cytotoxicity in ER+ MCF7 cells. MCF7 cells were treated with vehicle, R-pep
(100 μM), or ACT1 (100 μM) in the presence of drug vehicle (DMSO) or tamoxifen citrate (10 μM) for 48 hours and assessed for (A) crystal violet
staining density and quantitation by OD540. (B) R-pep and ACT1 treated cells were also assessed by cell counting after co-treatment with drug
vehicle (DMSO) or tamoxifen citrate (10 μM) for 48 hours. Student’s T-test was used to assess statistical significance as indicated. ± SEM; n = 3 (A)
n = 6 (B).
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dual ACT1 and tamoxifen treatment was more effective
than ACT1 alone or R-pep plus tamoxifen dual treatment
(Figure 4B).
ACT1 enhances lapatinib activity on HER2+ breast cancer
cells
To further test the ability of ACT1 to enhance targeted
agents, we next evaluated Cx43 targeting in HER2+ BT474
breast cancer cells. Here, we first evaluated BT474 cells for
ACT1 treatment-mediated effects on gap junction function
by gap-FRAP and found that ACT1 treatment enhanced
gap junction activity (Additional file 1: Figure S4A). Con-
sistent with this observation, we also observed increased
recruitment of Cx43 to the intercellular membrane border
upon ACT1 treatment in IF-labeled fixed cell preparations
(Additional file 1: Figure S4B). We next plated equal
numbers of BT474 cells treating them with water,
(100 μM) R-pep, or (100 μM) ACT1. Cells were then
additionally treated with vehicle (DMSO) or lapatinib at
1 nM, 10 nM or 50 nM concentrations; levels of lapati-
nib that are generally lower than required to kill BT474
cells. While relatively little effect was seen in DMSO
treated cells (Figure 5, first 3 columns), a significant
reduction of cells was seen in the cells treated with the
combination of ACT1 and lapatinib, with the most
prominent difference at 50 nM of lapatinib treatment
(Figure 5A). We next tested the effect of ACT1 and
lapatinib on BT474 mammosphere formation. A four
day drug treatment was performed after mammospheres
were allowed to initially form for 3 days. Consistent
with the above findings, we also observed a decrease in
primary mammosphere number when BT474 cells were
treated with the combination of ACT1 and lapatinib
(Figure 5B). Our findings indicate that ACT1 and lapatinibnegatively affected the ability of BT474 cells grow in 2D
culture and to initiate mammosphere formation in 3D
culture.
ACT1-mediated changes in proliferation and apoptosis
are differentially regulated in breast cancer cell lines
Previous studies suggest that downregulation of Cx43
increases proliferation and overexpression of Cx43 in-
hibits breast cancer cell proliferation [31]. However,
ACT1 does not alter Cx43 expression levels (Additional
file 1: Figure S1) [33,34]. To further pursue why prolifer-
ation was disrupted in MCF7 and MDA MB 231 cells
but not MCF10A or BT474 cells, we next evaluated ex-
pression levels of p27 in MCF10A, MCF7, and BT474
cells in response to R-pep or ACT1 treatment. We
chose to evaluate p27 because it was previously shown
that p27 is upregulated by Cx43 in osteosarcoma and
glioma cell lines resulting in cell cycle inhibition and
thus, impaired proliferation [45-47]. To examine the ef-
fect of ACT1 on p27, we treated MCF10A, MCF7, and
BT474 cells with R-pep or ACT1 and evaluated for p27
levels by immunoblotting. We found p27 levels were
not altered by ACT1 (Additional file 1: Figure S5) sug-
gesting that this is not the mechanism by which ACT1
inhibits proliferation. Subsequently, we pursued other
possible reasons for this difference in proliferation.
Because we observed differences in the effect of ACT1
on MCF10A versus MCF7 and MDA MB 231 cells as well
as differential distribution of Cx43 by IF in MCF10A cells,
this implied that Cx43 could be regulated differently in each
of these cell lines. Earlier studies established that a mechan-
ism of action for ACT1 is to disrupt Cx43 interaction with
the tight junction protein, zonula occludens 1 (ZO-1)
[33,34]. ACT1 mimics the C-terminal portion of Cx43 and
in doing so competitively binds to ZO-1, which normally
Figure 5 ACT1 enhances the effectiveness of lapatinib in HER2+ BT474 cells. (A) BT474 cells were treated with vehicle, R-pep (100 μM), or
ACT1 (100 μM) in the presence of drug vehicle (DMSO) or lapatinib (1, 10, 50 nM) for 48 hours and assessed for crystal violet staining density and
quantitation by OD540. Student’s T-test was used to assess statistical significance. *p≤ 0.001 when ACT1 compared to either R-pep or vehicle control.
(B) Combined treatment with ACT1 and lapatinib impairs BT474 mammosphere formation. BT474 cells were plated in ultra low adhesion 96-well plates
for 72 hours, followed by treatment with R-pep (100 μM) or ACT1 (100 μM) in the presence of drug vehicle (DMSO) or lapatinib (50 nM) for 96 hours.
At the end of the 7 day assays, wells were assessed for mammosphere number, which was used to calculate the mammosphere forming efficiency of
the cells. Student’s T-test was used to assess statistical significance as indicated. ± SEM; n = 4 (A) n = 24 (B).
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ity by sequestering Cx43 in a hemichannel state in the peri-
nexus [33,48], thus limiting the rate of gap junction
accretion. To evaluate the differences between the cell lines
used in this study, we assessed Cx43 expression levels and
the expression of its associated regulatory protein ZO-1. In
addition to MCF7 cells and MDA MB 231 cells, which rep-
resent ER+ and TNBC cell lines respectively, we also evalu-
ated BT474 HER2+ breast cancer cells. We found that
Cx43 expression levels differed between cell types, with
MCF10A and BT474 cells expressing low levels of Cx43 in
comparison to MCF7 and MDA MB 231, which showedhigher expression levels of Cx43 (Figure 6A). Additionally,
we found significantly higher levels of ZO-1 in BT474 cells
compared to the other three cell lines (Figure 6A) as well as
a higher level of ZO-1 in comparison to Cx43 in both the
MCF10A and BT474 cells. Consequently, if we calculated
the ratio of Cx43 to ZO-1 expression in each of the cell
lines, MCF10A and BT474 cells had very low Cx43 to
ZO-1 ratio whereas MCF7 and MDA MB 231 cells had
high levels of Cx43 compared to ZO-1 (Figure 6B). These
findings suggest that ZO-1 could play a more significant
role in regulating Cx43 in the BT474 cells and further im-
plies that ACT1 activity on BT474 cells could be different
Figure 6 Proliferation and apoptosis are differentially altered by ACT1 in MCF7 and BT474 breast cancer cell lines. (A) Whole cell
extracts isolated from MCF10A, MCF7, BT474, and MDA MB 231 cells were immunoblotted for Cx43 and ZO-1. (B) The ratio of Cx43 to ZO-1
expression was evaluated using the Odyssey imaging system. Cx43 and ZO-1 levels were normalized to β-tubulin expression. (C) MCF7 and BT474
cells were treated for 24 hours with R-pep (200 μM), ACT1 (200 μM), ACT1 plus Tamoxifen-MCF7, or ACT1 plus Lapatinib-BT474 and then analyzed
for cleaved-PARP (cl-PARP) expression. (D) MCF10A and BT474 lysates treated with R-pep (200 μM) or ACT1(200 μM) were immunoblotted for
cl-PARP and cleaved-Caspase-3 (cl-Caspase-3).
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such as MCF7 cells.
To further investigate how ACT1 treatment differs
between these two cell types we evaluated apoptosis.
MCF7 and BT474 cells were treated with R-pep, ACT1,
or a combination of ACT1 plus targeted inhibitors. We
treated MCF7 cells with ACT1 plus tamoxifen whereas
BT474 cells were treated with ACT1 plus lapatinib.
Cells were exposed to these agents for 24 hours and
then probed for cleaved-PARP as a marker for apop-
tosis. We found that ACT1 alone induced PARP cleav-
age in BT474 cells but had no effect on MCF7 cells
(Figure 6C and D). The combination of ACT1 and lapa-
tinib induced an even more robust response in the
BT474 cells (Figure 6C, bottom panel). While no apop-
tosis was observed in MCF7 cells treated with ACT1
alone, the addition of tamoxifen was able to induce PARP
cleavage suggesting that MCF7 cells may respond differ-
ently to ACT1 in terms of initiating cell death when com-
pared to BT474 cells, which were responsive to ACT1.
Our observations in Figure 6C also suggest that MCF7
cells undergo apoptosis mainly in response to tamoxifen.
We confirmed our findings with ACT1 in the BT474 cell
line by probing for a second apoptosis marker, cleaved-
Caspase-3, which was also elevated in response to ACT1treatment (Figure 6D). We also evaluated the effect of
ACT1 on inducing cell death in MCF10A cells. No apop-
tosis was observed in MCF10A cells in response to ACT1
(Figure 6D). We did not evaluate cleaved-Caspase-3 in
MCF7 cells because they do not express Caspase-3. Taken
together, these observations indicate that changes in prolif-
eration and apoptosis are differentially induced by ACT1 in
BT474 cells compared to MCF7 cells. Furthermore, as a
whole our findings show that combining ACT1 with the
targeted agents, lapatinib and tamoxifen, will enhance the
activity of these agents and argues for application of ACT1
as part of a combination regimen in breast cancer.
Discussion
Our current findings demonstrate a role for the gap
junction protein Cx43 in breast cancer growth and pro-
gression. Using a therapeutic agent, ACT1, that targets
endogenous Cx43 by stabilizing its activity at gap junc-
tions, we show that modulation of Cx43 signaling alters
breast cancer cell proliferation in the MCF7 and MDA
MB 231 cell lines. While these results are in agreement
with a tumor suppressive role for Cx43 [44], our find-
ings with the MDA MB 231 cell line is in disagreement
with previous findings that used Cx43 overexpression to
analyze proliferation of MDA MB 231 cells in 2D
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[31]. This difference in our findings could be attributed
to the possibility that high levels of Cx43 due to experi-
mental overexpression alters MDA MB 231 cells in a
manner that is dissimilar to modulation of endogenous
Cx43 via ACT1, and could point to important non-
junctional functions for Cx43 when overexpressed.
However, the details of this claim remain to be tested.
Based on our results, we assert that modulating gap
junction activity of endogenous Cx43 protein is an
important aspect of these studies and our findings are
consistent with a tumor suppressive role for Cx43.
Moreover, these findings indicate that treating breast
cancer cells with ACT1 is therapeutically beneficial due
to its ability to impair breast cancer cell proliferation.
Interestingly, we observe differential effects of ACT1
on proliferation between non-transformed MCF10A
cells and the MCF7 and MDA MB 231 breast cancer cell
lines. While this finding is a positive outcome for the
therapeutic use of ACT1, since normal cell function will
likely not be affected by ACT1 usage, this indicates that
differential regulation or activity of Cx43 could exist in
different cell types. Indeed, we found that Cx43 expres-
sion, localization, and gap junction activity was not
altered in response to ACT1 in MCF10A cells. Addition-
ally, we found that BT474 cells responded differently to
ACT1. In the BT474 cell line, cell number was not
affected by ACT1. Our data suggests, at least in part,
this difference in activity could be explained by a vari-
ation in Cx43 and ZO-1 levels in the different cell lines.
We report that Cx43 levels are reduced and ZO-1 levels
are increased in BT474 cells, which would likely affect
Cx43 activity since ZO-1 inhibits the gap junction activ-
ity of Cx43 [33,34]. Interestingly, we also found that
ACT1 induced apoptosis in BT474 cells but not in
MCF10A or MCF7 cells. These additional findings sug-
gest that the MCF7 and BT474 cells have different levels
of sensitivity and/or response to ACT1.
Interestingly, Cx43 levels were low in MCF10A cells
but were somewhat higher in the breast cancer cell lines
we evaluated. This raises the question of whether total
Cx43 levels are an appropriate analysis for Cx43’s role in
breast cancer, or if evaluating localization and/or activity
is more germane to establishing Cx43’s role. Moreover,
our observation that ZO-1 levels vary between cell types
should be taken into consideration when assessing Cx43
function in breast cancers, as ZO-1 negatively regulates
Cx43 gap junctional activity. Perhaps a better approach
would be to evaluate both Cx43 and ZO-1 in concert
with one another for a more complete picture. We add-
itionally evaluated the expression levels of two other
connexin proteins, Cx26 and Cx46, which have been
reported in breast cancer [13,49], and found that these
proteins were more robustly expressed in all three breastcancer cells lines when compared to MCF10A cells
(Additional file 1: Figure S6). However, the significance
of this finding remains to be addressed.
Recent evidence showed that the gap junction restor-
ing agent, PQ1, modulated Cx43 gap junction activity in
a colon cancer model [32]. Although PQ1 alters Cx43
activity, it is not specific for Cx43 as it also alters Cx46
expression [32,50] and may induce off-target effects [51].
One potential concern with the activity of PQ1 is that it
induces activation of AKT and the MAPKs ERK1/2 [32],
which are tumor promoting factors. Our findings indi-
cate that ACT1 treatment of MCF7 cells does not alter
AKT or ERK1/2 activity. Therefore, while PQ1 shows
therapeutic promise through targeting junctional connexins
and modulating apoptosis, the concomitant increases in
AKT and MAPK activity could eventually contribute to
therapeutic resistance. In line with this theory, AKT and
MAPK pathway alterations occur at high frequency in
breast cancers that become therapeutically resistant [52].
Our results indicate that therapeutic application of ACT1
would not share this effect.
While expression studies in human breast cancer samples
have shown that there is a loss of junctional Cx43 expres-
sion [17], previous findings have also indicated that total
Cx43 levels can fluctuate with breast cancer stage
[14-16,19]. One possibility is that impairing Cx43 from
reaching gap junctions, whether it be by downregulation or
mislocalization, is a primary adaptation for breast tumor
cells. Indeed, some reports indicate that a Cx43 pseudogene
exists in some cancers, which likely impairs Cx43 activity
[53]. However, other studies provide evidence that non-
junctional activities of Cx43 are likely important as well
[36,40]. At least two non-junctional mechanisms have been
proposed for Cx43, autophagy and apoptosis. Certainly,
these processes have been shown to impact breast cancer
progression and treatment [54]. Our current studies suggest
that treatment of MCF7 cells with the Cx43-targeted drug,
ACT1, does not impact autophagy, a result that is consist-
ent with previous findings that Cx43 inhibits autophagy in
a gap junction independent manner [40]. Previous findings
indicate that exogenous expression of Cx43 reduces the
expression of Bcl-2, an apoptosis inhibitory protein, and
induces apoptosis in a gap-junction independent manner
[36]. Since ACT1 specifically sequesters Cx43 to gap junc-
tions, it is unlikely that ACT1 alters Bcl-2 expression status
but this remains to be tested. Additional investigation into
the relationship between Cx43 and these processes would
be an important future endeavor.
Cx43 is regulated by the post-translational phosphoryl-
ation of serines (S364, S365, S325, S328, S330, S368,
S279, S282, S262) in the C-terminal domain of Cx43 and
depending on the site of phosphorylation, these pro-
cesses contribute to conformational changes and the for-
mation or disruption of gap junctions and gap junction
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has been shown to increase the phosphorylation of S368 in
an injury-dependent manner [59]. Whether S368 phos-
phorylation is affected by ACT1 in cancer cells may be an
important factor in mediating this bystander effect by creat-
ing a selective “distinct communication compartment”
[57]. Because a number of these Cx43 phosphorylation
sites are reported to regulate the localization of Cx43
independently of gap junction activity it is plausible that
non-junctional roles of Cx43 are also directly regulated
by phosphorylation events. This aspect of Cx43 signal-
ing remains to be uncovered and further applied to
understanding Cx43’s role in breast cancer.
In our present study we show combinatorial ACT1
treatment with tamoxifen and lapatinib enhanced the
effectiveness of these agents in MCF7 and BT474 breast
cancer cells, respectively. However, while ACT1 treat-
ment alone was able to alter MCF7 proliferation, it did
not appear to have a robust effect on BT474 cell num-
ber. In addition to the different expression levels of
Cx43 and ZO-1 we report, this result may be linked to
differences in Cx43 activity in ER-dependent versus
HER2-dependent cells. In support of the possibility that
differential effects could be observed in ER+ cells, previ-
ous studies have shown that Cx43 expression is regu-
lated by estrogen and is inversely correlated with ER
expression in human myometrial cultures and tissues
[60,61]. Genome expression analysis suggests that high
levels of Cx43 improves survival outcome of breast can-
cer patients with ER+ tumors but impairs survival out-
come in ER- and HER2+ cohorts [62,63]. Consequently,
the contribution of specific oncogenic drivers may have
an effect on Cx43 expression or activity in breast cancer
cells of different subtypes. Likewise, tamoxifen could in-
fluence Cx43 expression or activity. These disparities
would presumably impact ACT1’s activity toward Cx43
differentially in each individual breast cancer cell sub-
type, similar to the results that we report here. We note
that BT474 cells express ER, and certainly ER may be
modulated by ACT1 in these cells, but the proliferative
capacity of BT474 cells is largely dependent on HER2 as
the primary oncogenic driver. While additional investi-
gation is required to further elucidate ACT1’s impact on
ER expression, this line of reasoning provides possible
additional explanation for the differences in proliferation
and apoptosis we observe due to ACT1 treatment alone
in MCF7 cells compared with the response found in
BT474 cells.
Cx43 has been investigated in a HER2 model where
investigators used genetically engineered mouse models
to express a mutant form of Cx43 containing a glutam-
ine to a serine alteration at position 60 (G60S) that
localizes to gap junctions but has impaired gap junction
intercellular communication [28]. The researchers foundthat crossing G60S mutant mice with HER2-overexpressing
mice in which tumorigenesis is induced by carcinogen
(DMBA) exposure revealed unexpected findings where
G60S mice had delayed tumor onset but increased metasta-
sis [28]. Because of the use of DMBA as a carcinogen and
the gap junction dependent “bystander” effect, we are left
to question if the delayed tumor onset, despite loss of
Cx43-gap junction activity, could be due to an inability for
G60S animals to “see” the intercellular carcinogenic effects
of DMBA. Further studies are required to clarify these find-
ings. Regardless, our findings suggest that the combination
of targeting Cx43 with ACT1 with targeted inhibitors, dem-
onstrated here with tamoxifen and lapatinib, is beneficial in
breast cancer.
Finally, we found that combining ACT1 and lapatinib
reduced primary mammosphere formation in the BT474
model. Because mammosphere formation is typically
associated with cancer stem cell activity and survival of
cancer stem cells impacts cancer therapy as well as
development of resistance to cancer therapy [39], it is
enticing to speculate that modulation of Cx43 regulates
cancer stem cell proliferation or survival. However, as
we have only assessed primary mammosphere formation
and not propagation or self-renewal, care must be taken
when interpreting these findings. While our results pre-
sented in Figure 6 support our initial findings in 2D cul-
ture systems (Figure 5), additional studies are required
in order to determine whether ACT1 alters proliferation
or survival of tumor initiating cells or if it impacts tumor
stem cell renewal.
Conclusions
Our findings demonstrate that targeting the gap junctional
distribution and activity of Cx43 using ACT1 is effective in
breast cancer. Furthermore, ACT1 enhances the activity of
the targeted therapies, tamoxifen and lapatinib, supporting
the clinical potential of combinational strategies that
include modulation of Cx43 by ACT1.
Additional file
Additional file 1: Figure S1. Immunoblotting for total Cx43 protein
levels in whole cell extracts from MCF7 cells treated with vehicle, R-pep,
or ACT. Figure S2. (A) Immunoblotting for LC3B processing in MCF7 cells
treated with vehicle, R-pep, or ACT, in the presence or absence of chloroquine
(100 μM). (B) Immunoblotting for pAKT and pERK1/2 in whole cell extracts
from MCF7 cells treated with vehicle, R-pep, or ACT. Figure S3. (A) MCF10A
cells were treated with R-pep (200 μM), or ACT1 (200 μM) and assessed
for Immunofluoresence staining and imaging of Cx43 (green). Wheat
germ agglutinin (WGA) in red was used to stain cell membranes. (B)
MCF10A cells were treated with R-pep (200 μM) or ACT1 (200 μM) and
assessed for gap-FRAP. Figure S4. Connexin 43 activity and expression after
ACT1 treatment in BT474 cells. BT474 cells were treated with vehicle, R-pep
(200 μM), or ACT1 (200 μM) and assessed for (A) gap-FRAP. Dunnett’s Multiple
Comparison Test was used to determine statistical significance *= p<0.05 vs
Vehicle or R-Pep; ± SEM (B) Immunofluoresence staining and imaging of Cx43
(green) in BT474 cells treated with R-pep or ACT1. Wheat germ agglutinin
Grek et al. BMC Cancer  (2015) 15:296 Page 12 of 13(WGA) in red was used to stain cell membranes. Figure S5. p27 expression
levels are not altered by ACT1. Whole cell extracts isolated from MCF10A,
MCF7, and BT474 cells treated with R-pep (100 μM), or ACT1 (100 μM) were
immunoblotted for p27. Figure S6. Differential expression of Cx26 and Cx46
in non-transformed breast epithelial cells and breast cancer cell lines. Whole
cell extracts isolated from MCF10A, MCF7, BT474, and MDA MB 231 cells were
immunoblotted for Cx26 and Cx46.
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